Selected access changes across key treatment areas
June 2026 brings a diverse Belgian reimbursement update, with relevant patient access changes across osteoporosis, rare diseases, vaccines, oncology, immunology, smoking cessation and ophthalmology.
This overview highlights the main changes, without going into the full reimbursement detail.
Bone and mineral metabolism
Eladynos — abaloparatide — becomes reimbursed for severe postmenopausal osteoporosis.
This adds a new anabolic treatment option for patients with a recent major osteoporotic fracture, under specialist documentation requirements.
Rare diseases and hematology
Adzynma — apadamtase alfa — receives first reimbursement in congenital thrombotic thrombocytopenic purpura.
The reimbursement covers both acute treatment and prophylaxis in genetically confirmed cTTP, creating a formal reimbursed route for this ultra-rare condition.
Vaccines and infectious diseases
Gardasil 9 — human papillomavirus vaccine — expands reimbursed HPV prevention beyond the existing adolescent programme.
Reimbursement now includes adults aged 19 to under 31, as well as selected immunocompromised groups up to under 46.
Oncology and hematology
Calquence — acalabrutinib — enters reimbursement for adults with relapsed or refractory mantle cell lymphoma who have not previously received a BTK inhibitor.
Imbruvica — ibrutinib — becomes reimbursed in previously untreated mantle cell lymphoma as part of induction and maintenance treatment.
Yervoy — ipilimumab — is extended to adolescents aged 12 and older with advanced melanoma, both as monotherapy and in combination with Opdivo — nivolumab.
Opdivo — nivolumab — in dMMR/MSI-H colorectal cancer moves to continuation-only reimbursement. Existing patients can continue, but new patients can no longer start through this route.
Vargatef — nintedanib — exits reimbursement in the post-chemotherapy adenocarcinoma non-small-cell lung cancer setting.
Immunology, rheumatology and dermatology
Golimumab reimbursement language shifts from brand-centred to substance-based wording across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis.
Gobivaz — golimumab — is listed as the first golimumab biosimilar in Belgium.
Ilumetri — tildrakizumab — keeps its reimbursed position in severe adult plaque psoriasis, with mainly administrative updates.
Respiratory diseases and smoking cessation
Pulmozyme — dornase alfa — keeps its reimbursed cystic fibrosis criteria, with mainly documentation and specialist-responsibility updates.
Varenicline reimbursement moves toward substance-based wording. Varenicline EG is listed, while the access criteria for smoking cessation remain unchanged.
Ophthalmology
Eylea — aflibercept — sees its product-specific reimbursement paragraph for retinopathy of prematurity deleted.
At the same time, aflibercept moves into a more reference-linked and biosimilar-driven reimbursement environment, with Opuviz and Baiama entering the Belgian market.
Farmanaut take-away
June 2026 brings a mix of new reimbursements, broader indications, biosimilar-related updates and some route closures.
For clinicians and access teams, the most relevant changes are in severe osteoporosis, congenital TTP, HPV prevention, mantle cell lymphoma, advanced melanoma, colorectal cancer, rheumatology and retinopathy.
About Farmanaut
Farmanaut is a software-as-a-service platform that helps Belgian Market Access teams monitor reimbursement changes, track market access timelines and anticipate pricing and reimbursement strategy.
Want to see how Farmanaut can support your reimbursement monitoring? Contact us at info@digile.be for a demo.